In patients with uncontrolled asthma, a LAMA combined with an ICS and LABA in a single inhaler improved FEV1 and reduced exacerbations, according to data presented at ERS 2019 and reported by Healio.com.

  • Patients in the TRIMARAN trial received beclomethasone dipropionate 100 µg/formoterol fumarate 6 µg twice daily for two weeks.
  • Patients in the TRIGGER trial received beclomethasone dipropionate 200 µg/formoterol fumarate 6 µg in TRIGGER twice daily for two weeks.
  • Patients in TRIMARAN were then continued on standard combined therapy at the same dose (n = 576) or switched to extrafine beclomethasone dipropionate 100 µg/formoterol fumarate 6 µg/glycopyrronium 10 µg twice daily (n = 579) via a pressurized metered-dose inhaler.
  • Patients in TRIGGER continued on the same dose of standard combined therapy (n = 576) or switched to extrafine beclomethasone dipropionate 200 µg/formoterol fumarate 6 µg/glycopyrronium 10 µg twice daily via a pressurized metered-dose inhaler (n = 576) or switched to open-label standard combined therapy in a pressurized metered-dose inhaler plus tiotropium 2.5 µg twice daily via a soft mist inhaler (n = 288).
  • The researchers found that predose FEV1 at 26 weeks improved in the triple therapy group by 57 mL in TRIMARAN and by 73 mL in TRIGGER vs. standard combined therapy.

Read more at www.healio.com